Underpriced based on a past revenue structure that the Senate is about to squash. Not to mention the revenue obtained through this Balanced for Life program that could warrant major paybacks since there appears to be some patient solicitation involved. And... once the physicians realize that any and all of their financial involvement is going to be reported to the Senate Finance Committee, they are going to drop AMED like a, well you know, hot potato!
Sorry. Gentiva just leapfrogged over AMED in the hospice business. I wonder if AMED bid on ODSY's business. We need some acquisition news, but the senate investigation may cause AMED to hold off their plans.